MARKET

DBVT

DBVT

Dbv Technologies S A
NASDAQ
1.840
-0.070
-3.66%
Opening 09:48 09/29 EDT
OPEN
1.870
PREV CLOSE
1.910
HIGH
1.880
LOW
1.840
VOLUME
1.15K
TURNOVER
1.95K
52 WEEK HIGH
5.60
52 WEEK LOW
1.150
MARKET CAP
345.46M
P/E (TTM)
-2.7479
1D
5D
1M
3M
1Y
5Y
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session
Gainers
Benzinga · 1d ago
Algoma Steel Group, Sandstorm Gold And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 300 points on Wednesday. Here are some big stocks recording losses in today’s session.
Benzinga · 1d ago
European ADRs Move Higher in Wednesday Trading
European ADRs Move Higher in Wednesday Trading
MT Newswires · 1d ago
11 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Rubius Therapeutics (NASDAQ:RUBY) shares moved upwards by 30.46% to $0.59. The market value of their outstanding shares is at $53.5 million.
Benzinga · 6d ago
Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday
Gainers
Benzinga · 6d ago
Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday's Mid-Day Session
 Gainers
Benzinga · 09/22 16:26
Spero, HeartBeam top healthcare gainers; MediWound, Vincerx lead losers' pack
Gainers: Spero Therapeutics SPRO +135%. HeartBeam (BEAT) <font co...
Seekingalpha · 09/22 14:03
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Spero Therapeutics (NASDAQ:SPRO) shares moved upwards by 122.7% to $1.83 during Thursday&#39;s pre-market session. The market value of their outstanding shares is at $64.1 million.
Benzinga · 09/22 12:19
More
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Webull offers kinds of DBV Technologies SA - ADR stock information, including NASDAQ:DBVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DBVT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DBVT stock methods without spending real money on the virtual paper trading platform.